Andrew Thompson is a British scientist with over 30 years’ experience spanning academic research, drug discovery, global health and life science innovation. After completing his PhD in Neuropharmacology in 1998, he spent 15 years at the University of Cambridge, leading research into drug screening and target engagement. His work resulted in 75 peer-reviewed publications and was supported by organisations including the Wellcome Trust and British Heart Foundation.
Andrew subsequently managed national and international research programmes at Cambridge’s Department of Medicine, helping secure £12 million in funding and supporting rare disease research and international collaborations. Later, at PetMedix, he led monoclonal antibody development programmes to advance therapeutic candidate towards clinical studies.
In 2018, Andrew co-founded SMi Systems, where he is CEO. He has since led the company in securing over £10 million in funding, establishing UK and US facilities, and help develop a patented single-molecule imaging technology. His career has focuses on transforming drug discovery and diagnostics through highly sensitive, high-throughput molecular analysis.